Burning Rock Biotech (NASDAQ:BNR) Director Acquires 5,990 Shares

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) Director Yusheng Han acquired 5,990 shares of the firm’s stock in a transaction on Tuesday, June 23rd. The stock was purchased at an average cost of $7.50 per share, for a total transaction of $44,925.00. Following the completion of the acquisition, the director owned 18,129,186 shares in the company, valued at approximately $135,968,895. This represents a 0.03% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Yusheng Han also recently made the following trade(s):

• On Friday, June 26th, Yusheng Han bought 24,900 shares of Burning Rock Biotech stock. The shares were acquired at an average price of $8.00 per share, for a total transaction of $199,200.00.
• On Wednesday, June 24th, Yusheng Han purchased 250,000 shares of Burning Rock Biotech stock. The shares were bought at an average cost of $8.00 per share, for a total transaction of $2,000,000.00.
• On Monday, June 22nd, Yusheng Han purchased 104,650 shares of Burning Rock Biotech stock. The stock was bought at an average price of $7.45 per share, for a total transaction of $779,642.50.
• On Tuesday, June 16th, Yusheng Han bought 111,110 shares of Burning Rock Biotech stock. The stock was purchased at an average cost of $9.00 per share, for a total transaction of $999,990.00.
• On Friday, June 12th, Yusheng Han acquired 210,000 shares of Burning Rock Biotech stock. The stock was purchased at an average cost of $9.25 per share, for a total transaction of $1,942,500.00.
• On Thursday, June 11th, Yusheng Han purchased 24,760 shares of Burning Rock Biotech stock. The stock was acquired at an average price of $8.74 per share, for a total transaction of $216,402.40.

Burning Rock Biotech Stock Up 7.0%

Shares of NASDAQ BNR opened at $8.96 on Thursday. The company has a current ratio of 3.05, a quick ratio of 2.81 and a debt-to-equity ratio of 0.06. The company has a market cap of $94.26 million, a price-to-earnings ratio of -10.93 and a beta of 1.33. Burning Rock Biotech Limited Sponsored ADR has a 12 month low of $3.22 and a 12 month high of $41.72. The stock has a 50-day moving average price of $12.79 and a two-hundred day moving average price of $20.08.

Burning Rock Biotech (NASDAQ:BNR) last announced its quarterly earnings results on Tuesday, June 9th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($2.29) by $2.09. The company had revenue of $15.66 million during the quarter, compared to analysts’ expectations of $19.21 million. Burning Rock Biotech had a negative return on equity of 10.98% and a negative net margin of 11.57%.

Wall Street Analysts Forecast Growth

BNR has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Burning Rock Biotech in a research note on Monday, April 20th. Wall Street Zen lowered shares of Burning Rock Biotech from a “buy” rating to a “hold” rating in a report on Saturday, June 13th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Crcm LP raised its holdings in shares of Burning Rock Biotech by 121.8% in the 4th quarter. Crcm LP now owns 491,426 shares of the company’s stock worth $9,902,000 after acquiring an additional 269,851 shares during the last quarter. Renaissance Technologies LLC lifted its position in Burning Rock Biotech by 13.8% in the 1st quarter. Renaissance Technologies LLC now owns 35,407 shares of the company’s stock valued at $571,000 after acquiring an additional 4,290 shares in the last quarter. Prospera Financial Services Inc boosted its stake in Burning Rock Biotech by 26.0% during the 4th quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock valued at $628,000 after purchasing an additional 6,430 shares during the last quarter. Finally, Marshall Wace LLP acquired a new position in Burning Rock Biotech during the 4th quarter valued at about $220,000. Institutional investors and hedge funds own 30.03% of the company’s stock.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.